$ENVB
Enveric Biosciences, Inc. Stock $envb

$envb Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-Q Financial Statement

#000149315223040493 Filed on November 13, 2023

Income Statement

Concept	2023 Q4	2023 Q3	2022 Q3
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$930.7K	$2.010M	$3.515M
YoY Change	-67.02%	-42.81%	65.48%
% of Gross Profit
Research & Development	$1.369M	$1.352M	$2.056M
YoY Change	-27.69%	-34.24%	68.59%
% of Gross Profit
Depreciation & Amortization	$83.98K	$44.11K	$44.46K
YoY Change	-2.91%	-0.79%	-90.82%
% of Gross Profit
Operating Expenses	$2.384M	$1.352M	$2.056M
YoY Change	-50.35%	-34.24%	-41.55%
Operating Profit		-$3.448M	-$5.657M
YoY Change		-39.04%	60.85%
Interest Expense	$609.2K	$560.0K	$308.00
YoY Change	-62.44%	181718.18%	-183.24%
% of Operating Profit
Other Income/Expense, Net	-$1.639M	$632.8K	$3.178M
YoY Change	-448.82%	-80.09%	294.86%
Pretax Income	-$3.414M	-$2.816M	-$2.479M
YoY Change	-66.41%	13.58%	-8.61%
Income Tax	$22.32K	$6.595K
% Of Pretax Income
Net Earnings	-$3.436M	-$2.822M	-$2.479M
YoY Change	-60.96%	13.85%	-8.61%
Net Earnings / Revenue
Basic Earnings Per Share		-$1.30	-$1.46
Diluted Earnings Per Share	-$1.50	-$1.30	-$1.387M
COMMON SHARES
Basic Shares Outstanding	2.321M shares	2.148M shares	1.575M shares
Diluted Shares Outstanding		2.165M shares	1.787M shares

Balance Sheet

Concept	2023 Q4	2023 Q3	2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$2.288M	$4.270M	$21.20M
YoY Change	-87.09%	-79.86%	-1.15%
Cash & Equivalents	$2.288M	$4.267M	$21.20M
Short-Term Investments
Other Short-Term Assets	$1.294M	$1.560M	$1.066M
YoY Change	82.69%	46.37%	27.93%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$3.582M	$5.827M	$22.27M
YoY Change	-80.57%	-73.83%	-0.07%
LONG-TERM ASSETS
Property, Plant & Equipment	$507.4K	$539.2K	$712.9K
YoY Change	-25.11%	-24.38%	407.18%
Goodwill		$253.1K	$1.468M
YoY Change		-82.76%
Intangibles	$210.9K		$6.319M
YoY Change	-44.45%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$718.3K	$792.3K	$8.589M
YoY Change	-35.92%	-90.78%	-81.91%
TOTAL ASSETS
Total Short-Term Assets	$3.582M	$5.827M	$22.27M
Total Long-Term Assets	$718.3K	$792.3K	$8.589M
Total Assets	$4.300M	$6.619M	$30.86M
YoY Change	-78.01%	-78.55%	-55.77%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.219M	$1.098M	$710.3K
YoY Change	163.08%	54.61%	-67.16%
Accrued Expenses	$1.076M	$1.534M	$1.113M
YoY Change	-36.94%	37.79%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due			$0.00
YoY Change
Total Short-Term Liabilities	$2.344M	$4.184M	$2.598M
YoY Change	-41.35%	61.02%	20.13%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities			$2.514M
YoY Change			-20.59%
Total Long-Term Liabilities	$0.00	$0.00	$4.655M
YoY Change		-100.0%	47.04%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.344M	$4.184M	$2.598M
Total Long-Term Liabilities	$0.00	$0.00	$4.655M
Total Liabilities	$2.344M	$4.180M	$7.254M
YoY Change	-41.35%	-42.37%	-49.6%
SHAREHOLDERS EQUITY
Retained Earnings	-$96.50M	-$93.06M	-$70.53M
YoY Change	21.83%	31.95%
Common Stock	$27.39K	$21.82K	$20.78K
YoY Change	31.81%	4.99%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$1.956M	$2.436M	$22.84M
YoY Change
Total Liabilities & Shareholders Equity	$4.300M	$6.619M	$30.86M
YoY Change	-78.01%	-78.55%	-55.77%

Cashflow Statement

Concept	2023 Q4	2023 Q3	2022 Q3
OPERATING ACTIVITIES
Net Income	-$3.436M	-$2.822M	-$2.479M
YoY Change	-60.96%	13.85%	-8.61%
Depreciation, Depletion And Amortization	$83.98K	$44.11K	$44.46K
YoY Change	-2.91%	-0.79%	-90.82%
Cash From Operating Activities	-$1.754M	-$2.740M	-$4.550M
YoY Change	-49.33%	-39.79%	106.26%
INVESTING ACTIVITIES
Capital Expenditures	-$4.820K	$0.00	-$18.57K
YoY Change	-177.74%	-100.0%
Acquisitions
YoY Change
Other Investing Activities	-$3.150K	$0.00	$0.00
YoY Change			-100.0%
Cash From Investing Activities	$1.670K	$0.00	-$18.57K
YoY Change	-126.94%	-100.0%	-100.61%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-183.1K	-110.0K	7.824M
YoY Change		-101.41%	-78242300.0%
NET CHANGE
Cash From Operating Activities	-1.754M	-2.740M	-4.550M
Cash From Investing Activities	1.670K	0.000	-18.57K
Cash From Financing Activities	-183.1K	-110.0K	7.824M
Net Change In Cash	-1.936M	-2.850M	3.255M
YoY Change	-44.18%	-187.55%	283.36%
FREE CASH FLOW
Cash From Operating Activities	-$1.754M	-$2.740M	-$4.550M
Capital Expenditures	-$4.820K	$0.00	-$18.57K
Free Cash Flow	-$1.750M	-$2.740M	-$4.532M
YoY Change	-49.55%	-39.54%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q3	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent		usd
CY2023Q3	us-gaap	Preferred Stock Value PreferredStockValue		usd
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Central Index Key EntityCentralIndexKey	0000890821
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset		usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent		usd
CY2023Q3	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent		usd
CY2023Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent		usd
CY2023Q3	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount		usd
CY2023Q3	us-gaap	Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests		usd
CY2023Q3	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet		usd
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023Q3	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact		usd
CY2023Q3	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment		usd
CY2023Q2	us-gaap	Stock Redeemed Or Called During Period Value StockRedeemedOrCalledDuringPeriodValue		usd
CY2023Q2	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits		usd
CY2023Q3	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits		usd
CY2022Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross		usd
CY2022Q2	ENVB	Redeemable Noncontrolling Interest Value RedeemableNoncontrollingInterestValue		usd
CY2022Q2	ENVB	Stock Issued During Period Value Conversion Of Rstricted Stock Awards StockIssuedDuringPeriodValueConversionOfRstrictedStockAwards		usd
CY2022Q3	ENVB	Issuance Of Rounded Shares As Result Of Reverse Stock Split IssuanceOfRoundedSharesAsResultOfReverseStockSplit		usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment		usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment		usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts		usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
	us-gaap	Payments For Repurchase Of Redeemable Preferred Stock PaymentsForRepurchaseOfRedeemablePreferredStock		usd
	us-gaap	Proceeds From Repurchase Of Redeemable Preferred Stock ProceedsFromRepurchaseOfRedeemablePreferredStock		usd
	us-gaap	Interest Paid Net InterestPaidNet		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	ENVB	Warrants Issued In Conjunction With Notes Payable WarrantsIssuedInConjunctionWithNotesPayable		usd
	ENVB	Issuance Of Embedded Derivative IssuanceOfEmbeddedDerivative		usd
	ENVB	Issuance Of Redeemable Noncontrolling Series C Preferred Stock IssuanceOfRedeemableNoncontrollingSeriesCPreferredStock		usd
	ENVB	Issuance Of Redeemable Noncontrolling Series C Preferred Stock IssuanceOfRedeemableNoncontrollingSeriesCPreferredStock		usd
	ENVB	Offering Costs Accrued Not Paid OfferingCostsAccruedNotPaid		usd
	ENVB	Investment Options Issued In Conjunction With Common Stock Issuance InvestmentOptionsIssuedInConjunctionWithCommonStockIssuance		usd
	ENVB	Modification Of Warrants As Part Of Share Capital Raise ModificationOfWarrantsAsPartOfShareCapitalRaise		usd
CY2022Q4	us-gaap	Restructuring And Related Cost Cost Incurred To Date1 RestructuringAndRelatedCostCostIncurredToDate1		usd
CY2022Q4	ENVB	Prepaid Professional Fees PrepaidProfessionalFees		usd
CY2022Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts		usd
CY2022Q4	ENVB	Accrued Restructuring Costs AccruedRestructuringCosts		usd
CY2022Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent		usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2023Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1		usd
CY2023Q3	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount		usd
CY2023Q3	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-38286
	dei	Entity Registrant Name EntityRegistrantName	ENVERIC BIOSCIENCES, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	95-4484725
	dei	Entity Address Address Line1 EntityAddressAddressLine1	4851 Tamiami Trail N
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 200
	dei	Entity Address City Or Town EntityAddressCityOrTown	Naples
	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	34103
	dei	City Area Code CityAreaCode	(239)
	dei	Local Phone Number LocalPhoneNumber	302-1707
	dei	Security12b Title Security12bTitle	Common Stock, $0.01 par value per share
	dei	Trading Symbol TradingSymbol	ENVB
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	2321315	shares
CY2023Q3	us-gaap	Cash Cash	4266568	usd
CY2022Q4	us-gaap	Cash Cash	17723884	usd
CY2023Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1560354	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	708053	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	5826922	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	18431937	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	539152	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	677485	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	63817	usd
CY2023Q3	us-gaap	Goodwill Goodwill	253120	usd
CY2022Q4	us-gaap	Goodwill Goodwill	379686	usd
CY2023Q3	us-gaap	Assets Noncurrent AssetsNoncurrent	792272	usd
CY2022Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	1120988	usd
CY2023Q3	us-gaap	Assets Assets	6619194	usd
CY2022Q4	us-gaap	Assets Assets	19552925	usd
CY2023Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	1098233	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	463275	usd
CY2023Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1533829	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1705655	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	63820	usd
CY2023Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1250929	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	851008	usd
CY2023Q3	ENVB	Warrant Liabilities Current WarrantLiabilitiesCurrent	300557	usd
CY2022Q4	ENVB	Warrant Liabilities Current WarrantLiabilitiesCurrent	185215	usd
CY2022Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	727000	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	4183548	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3995973	usd
CY2022Q4	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	885028	usd
CY2022Q4	us-gaap	Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests	885028	usd
CY2023Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2023Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2181912	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2181912	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2078271	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2078271	shares
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	21818	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	20782	usd
CY2023Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	96013029	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	94395662	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-93063582	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-79207786	usd
CY2023Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-535619	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-536734	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	2435646	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	14671924	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	6619194	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	19552925	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2010349	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3514547	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7921340	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8783619	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1351750	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2055656	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5883440	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6134421	usd
CY2023Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	86296	usd
CY2022Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	86646	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	259300	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	241413	usd
CY2023Q3	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	3448395	usd
CY2022Q3	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	5656849	usd
	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	14064080	usd
	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	15159453	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-3448395	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-5656849	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-14064080	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-15159453	usd
CY2023Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-67822	usd
CY2022Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-1599623	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	115342	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-3845514	usd
CY2023Q3	us-gaap	Gain Loss On Investments GainLossOnInvestments	562715	usd
CY2022Q3	us-gaap	Gain Loss On Investments GainLossOnInvestments	1809622	usd
	us-gaap	Gain Loss On Investments GainLossOnInvestments	-399921	usd
	us-gaap	Gain Loss On Investments GainLossOnInvestments	1809622	usd
CY2022Q3	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-231000	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	727000	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-284000	usd
CY2023Q3	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	2237	usd
CY2022Q3	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-308	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	3142	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-5114	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	632774	usd
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	3177937	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	214879	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	5366022	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2815621	usd
CY2022Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2478912	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-13849201	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-9793431	usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	6595	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	6595	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-2822216	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-2478912	usd
	us-gaap	Net Income Loss NetIncomeLoss	-13855796	usd
	us-gaap	Net Income Loss NetIncomeLoss	-9793431	usd
CY2022Q3	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	12603	usd
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	19041	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	10433	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-2822216	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	2435646	usd
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	20411	usd
CY2022Q3	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	110991	usd
	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	147988	usd
	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	184985	usd
CY2023Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2822216	usd
CY2022Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2602506	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-14022825	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-9998827	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	10433	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-417390	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	1115	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-609695	usd
CY2023Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2811783	usd
CY2022Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3019896	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-14021710	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-10608522	usd
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.30
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.30
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.46
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.46
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-6.62
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-6.62
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-8.11
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-8.11
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2164656	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2164656	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1787235	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1787235	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2117153	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2117153	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1232936	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1232936	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	14671924	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	532835	usd
CY2023Q1	ENVB	Preferred Dividends Attributable To Redeemable Noncontrolling Interest PreferredDividendsAttributableToRedeemableNoncontrollingInterest	12329	usd
CY2023Q1	ENVB	Accretion Of Embedded Derivative To Redemption Value AccretionOfEmbeddedDerivativeToRedemptionValue	110991	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	1968	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-4677527	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	10405880	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	879738	usd
CY2023Q2	ENVB	Preferred Dividends Attributable To Redeemable Noncontrolling Interest PreferredDividendsAttributableToRedeemableNoncontrollingInterest	6712	usd
CY2023Q2	ENVB	Accretion Of Embedded Derivative To Redemption Value AccretionOfEmbeddedDerivativeToRedemptionValue	36997	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-11286	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-6356053	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	4874570	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	372859	usd
CY2022Q2	ENVB	Redeemable Noncontrolling Interest Embedded Derivative RedeemableNoncontrollingInterestEmbeddedDerivative	402000	usd
CY2022Q2	ENVB	Redeemable Noncontrolling Interest Issuance Costs RedeemableNoncontrollingInterestIssuanceCosts	41962	usd
CY2022Q2	ENVB	Issuance Of Redeemable Noncontrolling Series C Stock IssuanceOfRedeemableNoncontrollingSeriesCStock	-527	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	22305920	usd
CY2022Q1	ENVB	Stock Issued During Period Value Issued Direct Offering Net Of Offering Cost Three StockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCostThree	5802464	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	768619	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	88709	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-4524014	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	24441698	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	677543	usd
CY2022Q2	ENVB	Preferred Dividends Attributable To Redeemable Noncontrolling Interest PreferredDividendsAttributableToRedeemableNoncontrollingInterest	7808	usd
CY2022Q2	ENVB	Accretion Of Embedded Derivative To Redemption Value AccretionOfEmbeddedDerivativeToRedemptionValue	73994	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-281014	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-2790505	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	21965393	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	21965393	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	645137	usd
CY2022Q3	ENVB	Registered Direct Offering Pipe Offering Modification Of Warrants And Exercise Of Prefunded Warrants Net Of Offering Costs RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCosts	3249125	usd
CY2022Q3	ENVB	Preferred Dividends Attributable To Redeemable Noncontrolling Interest PreferredDividendsAttributableToRedeemableNoncontrollingInterest	12603	usd
CY2022Q3	ENVB	Accretion Of Embedded Derivative To Redemption Value AccretionOfEmbeddedDerivativeToRedemptionValue	110991	usd
CY2022Q3	us-gaap	Stock Redeemed Or Called During Period Value StockRedeemedOrCalledDuringPeriodValue	527	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-417390	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-2478912	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	22840286	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	22840286	usd
	us-gaap	Net Income Loss NetIncomeLoss	-13855796	usd
	us-gaap	Net Income Loss NetIncomeLoss	-9793431	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	115342	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-3845514	usd
	us-gaap	Gain Loss On Investments GainLossOnInvestments	-399921	usd
	us-gaap	Gain Loss On Investments GainLossOnInvestments	1809622	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	727000	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-284000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	1785432	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	2091299	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	64246	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	103365	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	126566	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	126563	usd
	us-gaap	Depreciation Depreciation	132734	usd
	us-gaap	Depreciation Depreciation	114850	usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	4219	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	746033	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	758419	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	429688	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-106675	usd
	ENVB	Increase Decrease In Right Of Use Operating Lease Liability IncreaseDecreaseInRightOfUseOperatingLeaseLiability	-64244	usd
	ENVB	Increase Decrease In Right Of Use Operating Lease Liability IncreaseDecreaseInRightOfUseOperatingLeaseLiability	-91022	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-12343363	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-13684606	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5195	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	577972	usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	16900	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	11705	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-577972	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	105000	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	17222100	usd
	us-gaap	Payments For Repurchase Of Redeemable Preferred Stock PaymentsForRepurchaseOfRedeemablePreferredStock	1052057	usd
	us-gaap	Proceeds From Repurchase Of Redeemable Preferred Stock ProceedsFromRepurchaseOfRedeemablePreferredStock	958038	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1157057	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	18180138	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	31399	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-72554	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-13457316	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	3845006	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	17723884	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	17355999	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	4266568	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	21201005	usd
	us-gaap	Interest Paid Net InterestPaidNet	5114	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	6595	usd
	ENVB	Warrants Issued In Conjunction With Notes Payable WarrantsIssuedInConjunctionWithNotesPayable	3595420	usd
	ENVB	Issuance Of Embedded Derivative IssuanceOfEmbeddedDerivative	402000	usd
	ENVB	Offering Costs Accrued Not Paid OfferingCostsAccruedNotPaid	20800	usd
	ENVB	Preferred Dividends Attributable To Redeemable Noncontrolling Interest PreferredDividendsAttributableToRedeemableNoncontrollingInterest	19041	usd
	ENVB	Preferred Dividends Attributable To Redeemable Noncontrolling Interest PreferredDividendsAttributableToRedeemableNoncontrollingInterest	20411	usd
	ENVB	Accretion Of Embedded Derivative To Redemption Value AccretionOfEmbeddedDerivativeToRedemptionValue	147988	usd
	ENVB	Accretion Of Embedded Derivative To Redemption Value AccretionOfEmbeddedDerivativeToRedemptionValue	184985	usd
	ENVB	Investment Options Issued In Conjunction With Common Stock Issuance InvestmentOptionsIssuedInConjunctionWithCommonStockIssuance	4323734	usd
	ENVB	Modification Of Warrants As Part Of Share Capital Raise ModificationOfWarrantsAsPartOfShareCapitalRaise	251357	usd
	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_808_eus-gaap--NatureOfOperations_zZOWzTBnJPt1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 1. <span id="xdx_820_z5d9H6FlAmac">BUSINESS AND LIQUIDITY AND OTHER UNCERTAINTIES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Nature of Operations</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enveric Biosciences, Inc. (“Enveric” or the “Company”) is a biotechnology company developing novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders. The head office of the Company is located in Naples, Florida. The Company has the following wholly-owned subsidiaries: Jay Pharma Inc. (“Jay Pharma”), 1306432 B.C. Ltd. (“HoldCo”), MagicMed Industries, Inc. (“MagicMed”), Enveric Canada Inc., and Enveric Therapeutics, Pty. Ltd. (“Enveric Therapeutics”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leveraging its unique discovery and development platform, The Psybrary™, Enveric has created a robust Intellectual Property portfolio of New Chemical Entities for specific mental health indications. Enveric’s lead program, the EVM201 Series, comprises next generation synthetic prodrugs of the active metabolite, psilocin. Enveric is developing the first product from the EVM201 Series – EB-373 – for the treatment of psychiatric disorders. Enveric is also advancing its second program, the EVM301 Series, expected to offer a first-in-class, new approach to the treatment of difficult-to-address mental health disorders, mediated by the promotion of neuroplasticity without also inducing hallucinations in the patient.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following the Company’s amalgamation with MagicMed completed in September 2021 (the “Amalgamation”), the Company has continued to pursue the development of MagicMed’s proprietary Psychedelic Derivatives library, the Psybrary™ which the Company believes will help to identify and develop the right drug candidates needed to address mental health challenges, including cancer-related distress. The Company synthesizes novel versions of classic psychedelics, such as psilocybin, DMT, mescaline and MDMA, using a mixture of chemistry and synthetic biology, resulting in the expansion of the Psybrary™, which includes 15 patent families with over a million potential variations and hundreds of synthesized molecules. Within the Psybrary™ the Company has three different types of molecules, Generation 1 (classic psychedelics), Generation 2 (pro-drugs), and Generation 3 (new chemical entities). The Company is working to add novel psychedelic molecular compounds and derivatives (“Psychedelic Derivatives”) on a regular basis through its work at the Company’s labs in Calgary, Alberta, Canada, where the Company has a team of PhD scientists with expertise in synthetic biology and chemistry. To date the Company has created over 500 molecules that are housed in the Psybrary™.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company screens newly synthesized molecules in the Psybrary™ through PsyAI™, a proprietary artificial intelligence (“AI”) tool. Leveraging AI systems is expected to reduce the time and cost of pre-clinical, clinical, and commercial development. The Company believes it streamlines pharmaceutical design by predicting ideal binding structures of molecules, manufacturing capabilities, and pharmacological effects to help determine ideal drug candidates, tailored to each indication. Each of these molecules that the Company believes are patentable can then be further screened to see how changes to its makeup alter its effects in order to synthesize additional new molecules. New compounds of sufficient purity are undergoing pharmacological screening, including non-clinical (receptors/cell lines), preclinical (animal), and ultimately clinical (human) evaluations. The Company intends to utilize the Psybrary™ and the AI tool to categorize and characterize the Psybrary™ substituents to focus on bringing more psychedelics-inspired molecules from discovery to the clinical phase.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Akos Spin-Off</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 11, 2022, the Company announced plans to transfer and spin-off its cannabinoid clinical development pipeline assets to Akos Biosciences, Inc. (formerly known as Acanna Therapeutics, Inc.), a majority-owned subsidiary of the Company (hereafter referred to as “Akos”), which was incorporated on April 13, 2022, by way of dividend to Enveric shareholders (the “Spin-Off”). As of May 12, 2023, the holders of the Company’s Akos Series A Preferred Stock, par value $<span id="xdx_906_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20230512__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zH0eJxeqbZ5" title="Preferred stock, par value">0.01</span> per share (“Akos Series A Preferred Stock”) have exercised this right to force redemption of all of the Akos Series A Preferred Stock for $<span id="xdx_900_eus-gaap--DividendsPayableAmountPerShare_iI_pid_c20230512__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zAlqNJHINDm3" title="Dividends, per share">1,000</span> per share, plus accrued but unpaid dividends of $<span id="xdx_900_ecustom--UnpaidDividends_c20230511__20230512__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zCidaWMzeCf9" title="Unpaid dividends">52,057</span> for a total of $<span id="xdx_901_eus-gaap--DividendsPreferredStock_c20230511__20230512_zUE8CUwd6b34" title="Dividends">1,052,057</span>. The Company made full payment on May 19, 2023. See Note 8.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Australian Subsidiary</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 21, 2023, the Company established Enveric Therapeutics, an Australia-based subsidiary, to support the Company’s plans to advance its lead program, the EVM201 Series, comprised of the next generation synthetic prodrugs of the active metabolite, psilocin (“EVM201 Series”), towards the clinic. Enveric Therapeutics will oversee the Company’s preclinical, clinical, and regulatory activities in Australia, including ongoing interactions with the local Human Research Ethics Committees (HREC) and the Therapeutic Goods Administration (TGA), Australia’s regulatory authority.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Going Concern, Liquidity and Other Uncertainties</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has incurred a loss since inception resulting in an accumulated deficit of $<span id="xdx_900_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_di_c20230930_zyyUvCe1Q1Y4" title="Accumulated deficit">93,063,582</span> as of September 30, 2023, and further losses are anticipated in the development of its business. Further, the Company had operating cash outflows of $<span id="xdx_90E_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_di_c20230101__20230930_zMdsI3DQIgIb" title="Net cash used in operating activities">12,343,363</span> for the nine months ended September 30, 2023. For the nine months ended September 30, 2023, the Company had a loss from operations of $<span id="xdx_902_eus-gaap--OperatingIncomeLoss_iN_di_c20230101__20230930_zpYlggpFTxq4" title="Loss from operations">14,064,080</span>. Since its inception, being a research and development company, the Company has not yet generated revenue and the Company has incurred continuing losses from its operations. The Company’s operations have been funded principally through the issuance of debt and equity. These factors raise substantial doubt about the Company’s ability to continue as a going concern for a period of one year from the issuance of these financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In assessing the Company’s ability to continue as a going concern, the Company monitors and analyzes its cash and its ability to generate sufficient cash flow in the future to support its operating and capital expenditure commitments. At September 30, 2023, the Company had cash of $<span id="xdx_902_eus-gaap--Cash_iI_c20230930_zSFLuh10xYv3" title="Cash">4,266,568</span> and working capital of $<span id="xdx_904_ecustom--WorkingCapital_iI_c20230930_zEJOSkTqVgoe" title="Working capital">1,643,374</span>. The Company’s current cash on hand is insufficient to satisfy its operating cash needs for the 12 months following the filing of this Quarterly Report on Form 10-Q. These conditions raise substantial doubt regarding the Company’s ability to continue as a going concern for a period of one year after the date the financial statements are issued. Management’s plan to alleviate the conditions that raise substantial doubt include reducing the Company’s rate of spend, managing its cash flow, advancing its programs, and raising additional working capital through public or private equity or debt financings or other sources, which has included the Equity Distribution Agreement with Canaccord for proceeds of up to $<span id="xdx_90D_eus-gaap--ProceedsFromShortTermDebt_pn5n6_c20230101__20230930__us-gaap--TypeOfArrangementAxis__custom--EquityDistributionAgreementMember_zt3c3qBJSUHh" title="Additional working capital">2.4</span> million (see Note 7) and the Purchase Agreement with Lincoln Park (see Note 10), subject to registration, and may include collaborations with additional third parties, as well as disciplined cash spending, to increase the Company’s cash runway. Adequate additional financing may not be available to the Company on acceptable terms, or at all. Should the Company be unable to raise sufficient additional capital, the Company may be required to undertake cost-cutting measures including delaying or discontinuing certain operating activities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s material cash requirements consist of working capital to fund capital expenditures incurred at their research facility in Calgary and their operations, which consist primarily of, without limitation, employee related expenses, product development activities conducted by third parties, research materials and lab supplies, facility related expenses including rent and maintenance, costs associated with preclinical studies, patent related costs, costs of regulatory and public company compliance, insurance costs, audit costs, consultants and legal fees. Additionally, the Company currently utilizes third-party contract research organizations (“CROs”) to assist with clinical development activities. If the Company obtains regulatory approval for any of their product candidates, they expect to incur significant expenses to engage third-party contract manufacturing organizations (“CMOs”) to carry out their clinical manufacturing activities as it does not yet have a commercialization infrastructure, and incur significant expenses related to developing its internal commercialization capability to support product sales, marketing and distribution. The Company’s current working capital resources are insufficient to fund these material cash requirements for the next twelve months.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As a result of these factors, management has concluded that there is substantial doubt about the Company’s ability to continue as a going concern for a period of one year after the date of the financial statements are issued. The Company’s unaudited condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Reduction in Force/Restructuring</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In May 2023, the Company entered into a cost reduction plan, including a reduction in force of approximately 35% of its full-time employees to streamline its operations and conserve cash resources. Additionally, contracts with seven consultants that were focused on the Akos cannabinoid spin-out were terminated. The Company recognized severance charges of approximately $<span id="xdx_909_eus-gaap--SeveranceCosts1_c20230501__20230531_zxu8RWK4igDi" title="Severance costs">453,059</span> through September 30, 2023. The plan included a focus on progressing the Company’s existing non-cannabinoid pipeline while reducing the rate of spend and managing cash flow. In June 2023, the Company completed the reduction in force, with such severance expenses recorded in general and administrative accounts.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 16, 2023, the Company entered into a separation agreement with Avani Kanubaddi, the Company’s President and Chief Operating Officer (the “Kanubaddi Separation Agreement”). In accordance with the Kanubaddi Separation Agreement, Mr. Kanubaddi’s outstanding restricted stock units (“RSUs”) will retain their vesting conditions. Mr. Kanubaddi’s 2023 salary and benefits of $<span id="xdx_90C_eus-gaap--SalariesAndWages_c20230615__20230616__us-gaap--TypeOfArrangementAxis__custom--KanubaddiSeparationAgreementMember_zix7YcCkanme" title="Salaries and benefit">550,974</span> were accrued and will be paid out in twelve equal monthly installments beginning in July 2023. Upon termination, any unvested time-based RSUs became fully vested. The Company accelerated expense recognized related to these shares that vested was $<span id="xdx_907_ecustom--ExpenseRelatedToAccelerationOfVesting_c20230615__20230616__us-gaap--TypeOfArrangementAxis__custom--MrKanubaddiEmploymentAgreementMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zTwurjCl2yW5" title="Expense related to acceleration of vesting">231,273</span>. Of the <span id="xdx_906_ecustom--MarketPerformanceBasedShares_iI_c20230616__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zwjR13z5wUke" title="Market performance based shares">11,278</span> market performance-based RSUs previously granted, <span id="xdx_902_ecustom--MarketPerformanceBasedShares_iI_c20230616__us-gaap--TypeOfArrangementAxis__custom--MrKanubaddiEmploymentAgreementMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zmKplWzf0dE9" title="Market performance based shares">3,759</span> will continue to be subject to the original terms and conditions of Mr. Kanubaddi’s employment agreement and the remainder were forfeited.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p> <p id="xdx_899_eus-gaap--ScheduleOfRestructuringAndRelatedCostsTextBlock_zvmyhp9yqXog" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BD_zh4bX6A308Zj" style="display: none">SCHEDULE OF RESTRUCTURING COSTS PAYABLE</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Accrued Restructuring Costs</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: right">January 1, 2023 Beginning balance</td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--RestructuringAndRelatedCostCostIncurredToDate1_iS_c20230101__20230930_zPNSGCYsvV6g" style="text-align: right" title="Restructuring cost payable, beginning"><span style="-sec-ix-hidden: xdx2ixbrl0999">—</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 40%; text-align: right">Restructuring costs incurred</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--RestructuringAndRelatedCostIncurredCost_c20230101__20230930_zGmeHs9oE1gb" style="width: 56%; text-align: right" title="Restructuring costs incurred">1,004,033</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: right; padding-bottom: 1.5pt">Restructuring costs paid</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--RestructuringCosts_c20230101__20230930_zr45BgIf8gN8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Restructuring costs">(396,431</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: right; padding-bottom: 2.5pt">September 30, 2023 ending balance</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--RestructuringAndRelatedCostCostIncurredToDate1_iE_c20230101__20230930_zqxBK6O1Ejm2" style="border-bottom: Black 2.5pt double; text-align: right" title="Restructuring cost payable, ending">607,602</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A1_ziTdDqB4gdc8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Inflation Risks</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company considers the current inflationary trend existing in the North American economic environment reasonably likely to have a material unfavorable impact on results of continuing operations. Higher rates of price inflation, as compared to recent prior levels of price inflation, have caused a general increase in the cost of labor and materials. In addition, there is an increased risk of the Company experiencing labor shortages due to a potential inability to attract and retain human resources due to increased labor costs resulting from the current inflationary environment.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q2	us-gaap	Dividends Preferred Stock DividendsPreferredStock	1052057	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-93063582	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-12343363	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-14064080	usd
CY2023Q3	us-gaap	Cash Cash	4266568	usd
CY2023Q3	ENVB	Working Capital WorkingCapital	1643374	usd
CY2023Q2	us-gaap	Severance Costs1 SeveranceCosts1	453059	usd
	us-gaap	Restructuring And Related Cost Incurred Cost RestructuringAndRelatedCostIncurredCost	1004033	usd
	us-gaap	Restructuring Costs RestructuringCosts	-396431	usd
CY2023Q3	us-gaap	Restructuring And Related Cost Cost Incurred To Date1 RestructuringAndRelatedCostCostIncurredToDate1	607602	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_846_eus-gaap--UseOfEstimates_zrbmf91SDFOc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86E_zXPqm69fXUP9">Use of Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amount of assets and liabilities at the date of the financial statements and expenses during the periods reported. By their nature, these estimates are subject to measurement uncertainty and the effects on the financial statements of changes in such estimates in future periods could be significant. Significant areas requiring management’s estimates and assumptions include determining the fair value of transactions involving common stock and the valuation of stock-based compensation, accruals associated with third party providers supporting research and development efforts, and estimated fair values of long lived assets used to record impairment charges related to intangible assets. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_844_eus-gaap--ConcentrationRiskCreditRisk_z0QdQQNDZ0N4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86E_zhuvd1vi2PU7">Concentration of Credit Risk</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which at times, may exceed the federal depository insurance coverage of $<span id="xdx_90B_eus-gaap--CashFDICInsuredAmount_iI_c20230930__srt--StatementGeographicalAxis__country--US_z8pdxhOi2v0i" title="Cash FDIC insured amount">250,000</span> in the United States and Australia and $<span id="xdx_907_eus-gaap--CashFDICInsuredAmount_iI_c20230930__srt--StatementGeographicalAxis__country--CA_z7aoJ0vi7a42" title="Cash insured amount">100,000</span> in Canada. The Company has not experienced losses on these accounts, and management believes the Company is not exposed to significant risks on such accounts. As of September 30, 2023, the Company had greater than $<span id="xdx_909_eus-gaap--CashFDICInsuredAmount_iI_c20230930__srt--StatementGeographicalAxis__country--US_ze0UQJhWZzo8" title="Cash FDIC insured amount">250,000</span> at United States financial institutions, less than $<span id="xdx_900_eus-gaap--CashFDICInsuredAmount_iI_c20230930__srt--StatementGeographicalAxis__country--AU_zN1c7ZXUhIs2" title="Cash FDIC insured amount">250,000</span> at Australian financial institutions, and greater than $<span id="xdx_907_eus-gaap--CashFDICInsuredAmount_iI_c20230930__srt--StatementGeographicalAxis__country--CA_zBJaSOX7bAV2" title="Cash FDIC insured amount">100,000</span> at Canadian financial institutions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q3	us-gaap	Deferred Offering Costs DeferredOfferingCosts	125800	usd
CY2023Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1880843	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1880843	shares
CY2022Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1875811	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1875811	shares
CY2023Q3	ENVB	Prepaid Research And Development PrepaidResearchAndDevelopment	651623	usd
CY2022Q4	ENVB	Prepaid Research And Development PrepaidResearchAndDevelopment	268686	usd
CY2023Q3	us-gaap	Prepaid Taxes PrepaidTaxes	229909	usd
CY2022Q4	us-gaap	Prepaid Taxes PrepaidTaxes	159782	usd
CY2023Q3	ENVB	Prepaid Professional Fees PrepaidProfessionalFees	74500	usd
CY2023Q3	us-gaap	Prepaid Insurance PrepaidInsurance	332508	usd
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	174406	usd
CY2023Q3	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	146014	usd
CY2022Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	105179	usd
CY2023Q3	us-gaap	Deferred Offering Costs DeferredOfferingCosts	125800	usd
CY2023Q3	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	18000	usd
CY2022Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	251333	usd
CY2023Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1560354	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	708053	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	379686	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	126566	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	253120	usd
CY2023Q3	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0	usd
CY2022Q3	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0	usd
	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0	usd
	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0	usd
CY2023Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	42191	usd
CY2022Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	42191	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	126566	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	126563	usd
CY2023Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	307067	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	178775	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	539152	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	677485	usd
CY2023Q3	us-gaap	Depreciation Depreciation	44105	usd
CY2022Q3	us-gaap	Depreciation Depreciation	44458	usd
	us-gaap	Depreciation Depreciation	132734	usd
	us-gaap	Depreciation Depreciation	114850	usd
CY2023Q3	ENVB	Accrued Product Development Cost AccruedProductDevelopmentCost	94663	usd
CY2022Q4	ENVB	Accrued Product Development Cost AccruedProductDevelopmentCost	195104	usd
CY2023Q3	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	729616	usd
CY2022Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	1175963	usd
CY2023Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	74499	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	83255	usd
CY2023Q3	ENVB	Accrued Restructuring Costs AccruedRestructuringCosts	607602	usd
CY2023Q3	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	9449	usd
CY2023Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1533829	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1705655	usd
	us-gaap	Common Stock Voting Rights CommonStockVotingRights	The holders of the Company’s common stock are entitled to one vote per share
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Description ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription	(i) increase the aggregate number of shares available for the grant of awards by 146,083 shares to a total of 200,000 shares, and (ii) add an “evergreen” provision whereby the number of shares authorized for issuance pursuant to awards under the Incentive Plan will be automatically increased on the first trading date immediately following the date the Company issues any share of Common Stock (defined below) to any person or entity, to the extent necessary so that the number of shares of the Company’s Common Stock authorized for issuance under the Incentive Plan will equal the greater of (x) 200,000 shares, and (y) 15% of the total number of shares of the Company’s Common Stock outstanding as of such issuance date. The Plan Amendment was approved by the Company’s shareholders at a special meeting of the Company’s shareholders held on July 14, 2022
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	48329	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	37.05
CY2022Q4	ENVB	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue	44.82
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y1M6D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	16476	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	5.79
	ENVB	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeited Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedWeightedAverageGrantDateFairValue	5.80
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	31852	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	53.18
CY2023Q3	ENVB	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue	74.04
	ENVB	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm	P3Y4M24D
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	24626	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	63.72
CY2023Q3	ENVB	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue	86.52
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P3Y
CY2023Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	328253	usd
CY2022Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	590190	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1638365	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1932553	usd
CY2023Q2	us-gaap	Derivative Liabilities DerivativeLiabilities	714000	usd
CY2022Q4	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	885028	usd
	us-gaap	Temporary Equity Stock Issued During Period Value New Issues TemporaryEquityStockIssuedDuringPeriodValueNewIssues	19041	usd
	us-gaap	Temporary Equity Accretion To Redemption Value TemporaryEquityAccretionToRedemptionValue	147988	usd
	us-gaap	Payments For Repurchase Of Redeemable Preferred Stock PaymentsForRepurchaseOfRedeemablePreferredStock	1052057	usd

Files In Submission

Name	View Source	Status
0001493152-23-040493-index-headers.html	Edgar Link	pending
0001493152-23-040493-index.html	Edgar Link	pending
0001493152-23-040493.txt	Edgar Link	pending
0001493152-23-040493-xbrl.zip	Edgar Link	pending
envb-20230930.xsd	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
envb-20230930_cal.xml	Edgar Link	unprocessable
envb-20230930_def.xml	Edgar Link	unprocessable
envb-20230930_lab.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
form10-q_htm.xml	Edgar Link	completed
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
envb-20230930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ENVB
Enveric Biosciences, Inc. Stock $envb

2023 Q4 Form 10-Q Financial Statement

#000149315223040493 Filed on November 13, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ENVB Enveric Biosciences, Inc. Stock $envb

2023 Q4 Form 10-Q Financial Statement

#000149315223040493 Filed on November 13, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ENVB
Enveric Biosciences, Inc. Stock $envb